Novel apovincaminic acid derivatives
    2.
    发明授权
    Novel apovincaminic acid derivatives 失效
    新型氨基丁酸衍生物

    公开(公告)号:US4614824A

    公开(公告)日:1986-09-30

    申请号:US754671

    申请日:1985-07-11

    CPC分类号: C07D461/00

    摘要: The invention relates to new racemic and optically active apovincaminic acid derivatives of the general formula (I) ##STR1## wherein A is hydroxyl, halogen or a group --O--(CH.sub.2).sub.n --OR.sup.1 or --OMe, in whichR.sup.1 is alkyl having from one to 6 carbon atoms,n is an integer between 2 and 6,Me is an alkali metal,R.sup.2 stands for an alkyl group having from one to 6 carbon atoms, which may be identical with or different from R.sup.1,and the hydrogen in the 3-position and the R.sup.2 group have an .alpha.,.alpha.- and/or .beta.,.beta.- or .alpha.,.beta.- and/or .beta.,.alpha.-configuration, and pharmaceutically acceptable acid addition salts thereof, which are pharmaceutically active, e.g. show antihypoxial activity or are potent peripheral vasodilators. Their preparation and pharmaceutical composition containing them are also within the scope of the invention.

    摘要翻译: 本发明涉及通式(I)的新的外消旋和光学活性氨基丁酸衍生物,其中A是羟基,卤素或-O-(CH2)n-OR1或-OMe基团,其中R1 是具有1至6个碳原子的烷基,n是2和6之间的整数,Me是碱金属,R 2表示具有1至6个碳原子的烷基,其可以与R 1相同或不同, 3-位和R2基团中的氢具有药学活性的α,α - 和/或β,β-或α,β-和/或β,α-构型及其药学上可接受的酸加成盐 ,例如 显示抗低氧活性或是有效的外周血管扩张剂。 它们的制备和含有它们的药物组合物也在本发明的范围内。

    Process for the preparation of eburnamonine derivatives
    4.
    发明授权
    Process for the preparation of eburnamonine derivatives 失效
    制备苯丙胺衍生物的方法

    公开(公告)号:US4464535A

    公开(公告)日:1984-08-07

    申请号:US438288

    申请日:1982-11-01

    CPC分类号: C07D471/14 C07D461/00

    摘要: The invention relates to a new process for the preparation of eburnamonine derivatives of the general Formula I ##STR1## (wherein R.sup.1 is an alkyl group having 1-6 carbon atoms) and optical and geometrical isomers thereof which comprises reacting a hydroxyimino-octahydro-indolo[2,3-a]quinolizine derivative of the general Formula II ##STR2## (wherein R.sup.1 is as stated above and R.sup.2 stands for an alkyl group having 1-6 carbon atoms being identical with or different from R.sup.1, or a hydrogen atom) or an acid addition salt thereof in an organic protic solvent or solvent mixture with an inorganic base, optionally under the addition of water or an aqueous mineral acid, at a temperature between 60.degree. C. and 200.degree. C.The compounds of the present invention are known drugs having blood pressure decreasing and cerebral vasodilatatory effect. The advantage of the process of the present invention is that it is readily feasible on industrial scale too, provides isomer-free pure products with high yield and requires the use of readily available simple starting materials.

    摘要翻译: 本发明涉及一种制备通式Ⅰ(I)(Ⅰ)(其中R1是具有1-6个碳原子的烷基)及其光学和几何异构体的本发明化合物的新方法,其包括使羟基亚氨基 - 通式II的八氢 - 吲哚并[2,3-a]喹嗪衍生物(II)(其中R 1如上所述,R 2表示具有1-6个碳原子的烷基,与R 1相同或不同) ,或氢原子)或其酸加成盐在无机碱的有机质子溶剂或溶剂混合物中,任选在水或无机酸水溶液中,在60℃至200℃的温度下进行。 本发明的化合物是具有降血压和脑血管扩张作用的已知药物。 本发明方法的优点是在工业规模上也容易实现,提供高产率的无异构体纯产品,并且需要使用容易获得的简单起始原料。

    Process for an enantioselective synthesis of optically active
14-oxo-E-homo-eburnane derivatives
    5.
    发明授权
    Process for an enantioselective synthesis of optically active 14-oxo-E-homo-eburnane derivatives 失效
    光学活性的14-氧代 - 均 - 伊本恩衍生物的对映选择性合成方法

    公开(公告)号:US4399069A

    公开(公告)日:1983-08-16

    申请号:US312128

    申请日:1981-10-16

    CPC分类号: C07D471/14

    摘要: The invention relates to a new enantioselective synthesis for the preparation of optically active 14-oxo-E-homo-eburnane derivatives of the formula (Ia) ##STR1## wherein R.sup.1 is alkyl having from 1 to 4 carbon atom. In the synthesis optically active 6-alkoxycarbonylhexahydroindoloquinolizinium salts are employed as starting materials, which contain a center of chirality at the site of attachment of the carboxyl group. This center of chirality preserves the optical activity of the optically active tryptophan ester from which this compound has been prepared until a new center of chirality is formed in the molecule in a configuration corresponding to the desired end product. The carboxyl group, which is not needed in the end product and only serves to preserving the optical activity can then be eliminated.Compounds of the formula (Ia) are known in the art and may be used in the synthesis of (+)-vincamine and (+)-apovincaminic acid ethylester.

    摘要翻译: 本发明涉及用于制备式(Ia)的光学活性的14-氧代-E-高 - 同型异烟酸衍生物的新的对映选择性合成。其中R 1是具有1至4个碳原子的烷基。 在合成光学活性中,使用6-烷氧基羰基六氢吲哚喹啉鎓盐作为起始原料,其在羧基连接位点含有手性中心。 该手性中心保留了光学活性色氨酸酯的光学活性,从该化合物已经制备出光学活性,直至在分子中形成对应于所需最终产物的构型的新的手性中心。 然后可以消除最终产物中不需要的仅用于保持光学活性的羧基。 式(Ia)的化合物是本领域已知的,可用于合成(+) - 长春胺和(+) - 氨基丁酸乙酯。

    Process for the preparation of vincaminic acid esters
    9.
    发明授权
    Process for the preparation of vincaminic acid esters 失效
    用于制备长春酸酯的方法

    公开(公告)号:US4464534A

    公开(公告)日:1984-08-07

    申请号:US425866

    申请日:1982-09-28

    IPC分类号: C07D461/00 C07D455/00

    CPC分类号: C07D461/00

    摘要: The invention relates to a new process for the preparation of apovincaminic acid esters. More particularly, the invention concerns a process for preparing racemic and optionally active vincaminic acid esters of the formula (I) ##STR1## in which R.sup.1 and R.sup.2 independently stand for alkyl having from one to 6 carbon atoms, and 14-epimers thereof.According to the invention an octahydroindolo[2,3-a]quinolizine-oxime ester of the formula (II) ##STR2## in which R.sup.1 and R.sup.2 have the same meaning as defined above, is reacted with an aqueous solution of sulfurous acid or a salt thereof at a temperature of 80.degree. to 110.degree. C. and the 14-epimeric mixture obtained is epimerized or separated in a known manner and if desired, the racemic vincaminic acid esters are resolved.The valuable, pharmaceutically active compounds of the formula (I) can be prepared according to the invention in a considerably improved yield and the undesired side reactions can be suppressed and/or the by-products can easily be converted into other pharmaceutically active materials.

    摘要翻译: 本发明涉及一种用于制备氨磷酸酯的新方法。 更具体地说,本发明涉及一种制备式(I)的外消旋和任选活性的长春胺酸酯的方法,其中R 1和R 2独立代表具有1至6个碳原子的烷基,和14-差向异构体 其中。 根据本发明,其中R 1和R 2具有与上述相同的含义的式(II)的二氢吲哚并[2,3-a]喹嗪肟酯与其中的亚硫酸酯水溶液 酸或其盐,并且所得的14-差向异构体混合物以已知方式进行差向异构化或分离,如果需要,外消旋的长春碱酯被分解。 式(I)的有价值的药物活性化合物可以按照本发明以显着提高的产量制备,并且可以抑制不期望的副反应和/或副产物可以容易地转化成其它药物活性物质。